Krsnaa Diagnostics Board Approves ₹430 Cr NCD Issuance

Krsnaa Diagnostics board approves issuance of unlisted, secured NCDs worth ₹430 crores on private placement basis with 7-year tenure and half-yearly redemption schedule.

Krsnaa Diagnostics Reports 11% Revenue Growth and 29% EBITDA Margin in Q2 FY26

Krsnaa Diagnostics achieved revenue of Rs. 206 crores with 11% year-on-year growth and EBITDA of Rs. 60 crores at 29% margin, driven by operational efficiency improvements and retail expansion. The company operates over 200 CT and MRI centers across 18 states and expects meaningful revenue acceleration from Q4 FY25 with Rajasthan PPP project implementation progressing on schedule.

Krsnaa Diagnostics Reports 22% Jump in Quarterly Profit to INR 239 Million

Krsnaa Diagnostics achieved quarterly profit of INR 239 million, marking a 22% year-over-year increase from INR 196 million. Revenue grew 11% to INR 2,060 million while EBITDA rose 18% to INR 602 million with margins expanding to 29% from 27%. The company served 5.4 million patients and performed 16.4 million tests. Krsnaa operates across 18 states with 120 centers and maintains 57 NABL-accredited pathology labs and 36 NABH-accredited imaging centers. The diagnostic services provider offers testing at rates approximately 70% below market prices across radiology, pathology, and tele-radiology services through its public-private partnership model.